The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Arbutus stock jumps as Moderna settlement payment deadline nears
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 7, 2:45 PM EDT

Arbutus stock jumps as Moderna settlement payment deadline nears

ABUS investors are watching a July 8 date tied to Moderna’s $950 million upfront payment under a long-running patent settlement, after which Arbutus expects to receive about $179 million net of costs.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Shares of Arbutus Biopharma climbed as investors positioned for an upcoming payment from Moderna tied to a resolved patent dispute over technology used in Moderna’s COVID-19 vaccines.

The market move follows a settlement announced earlier that resolves claims that Moderna used Arbutus’s patented technology without authorization. In the dispute, the central issue involved lipid nanoparticles, or LNPs, the tiny fat-based delivery particles that help mRNA therapies enter human cells and that are critical to the performance of mRNA vaccines such as Moderna’s Spikevax.

According to coverage of the deal, Moderna is required under the agreement to make a $950 million upfront payment by July 8. The total settlement was described as potentially reaching up to $2.25 billion, but the immediate catalyst for traders is the near-term cash transfer tied to the upfront portion.

Arbutus expects to receive approximately $179 million of the July 8 payment after costs, with the remainder of the upfront amount directed to Genevant Sciences, described in the coverage as a unit of Roivant Sciences. Investors appeared to treat Arbutus’s expected net proceeds as a near-term financial inflection point.

The patent litigation backdrop underscores why the agreement matters commercially even years after the pandemic. The coverage said Arbutus had developed and patented specific LNP formulations prior to COVID-19, while Moderna’s vaccines relied on LNP delivery systems to transport mRNA into patients. The settlement was characterized as a resolution to a long-running dispute over whether the technology used in Moderna’s vaccines overlapped with Arbutus’s patents.

Arbutus did not, in the published post, provide additional detail on the timing or mechanics of any subsequent capital-return actions beyond indicating it was evaluating options once the funds arrive. The same coverage said the company plans to consider returning capital to shareholders later this year after receipt of the payment.

Market participants also appeared to focus on the fact that the settlement is not merely theoretical or back-ended. An upfront payment requirement creates a defined window for when cash could land on the balance sheet, which often tightens market expectations ahead of the deadline.

Still, several details remain outside the public snapshot from the post. It does not disclose whether there are conditions that could delay payment, nor does it provide the exact schedule for distribution of proceeds among parties beyond the stated net expectation for Arbutus and the remainder for Genevant Sciences. Investors will likely look for additional confirmation from company disclosures closer to the payment date.

Why It Matters

  • For Arbutus, the July 8 upfront payment acts as a concrete near-term catalyst tied to the settlement’s cash flow.
  • The case highlights how intellectual-property disputes over core delivery technology like LNPs can resurface years later as litigation winds down.
  • A large, expected net proceeds figure can influence how investors think about Arbutus’s balance sheet and potential shareholder capital-return plans.
  • The outcome also reinforces the commercial leverage of platform-enabling technology patents in the life sciences sector, especially in high-visibility areas like vaccines.

Sources

Key Facts

  • Arbutus Biopharma (ABUS) rose as investors awaited a Moderna settlement payment.
  • The underlying dispute centered on whether Moderna used Arbutus’s patented technology in its COVID-19 vaccines.
  • The settlement described in the coverage required Moderna to make a $950 million upfront payment by July 8.
  • Arbutus expects to receive about $179 million of the upfront amount net of costs.
  • Coverage indicated the remaining upfront proceeds go to Genevant Sciences, described as a unit of Roivant Sciences (ROIV).
  • The dispute involved lipid nanoparticles (LNPs), which deliver mRNA into human cells and are important for mRNA vaccine effectiveness.

Healthcare Related

Arbutus stock jumps as Moderna settlement payment deadline nears | The Apex Times